Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 8/2022

19-06-2022 | Cholangiocarcinoma | Original Article

Microsatellite instability in patients with hepato-biliary-pancreatic malignancies in clinical practice (KHBO 1903)

Authors: Shoji Kubo, Hiroaki Nagano, Masanori Tsujie, Satoru Seo, Kunihito Gotoh, Hiroshi Wada, Shinsuke Nakashima, Tatsuya Ioka

Published in: International Journal of Clinical Oncology | Issue 8/2022

Login to get access

Abstract

Background

This study aimed to determine the prevalence of microsatellite instability (MSI)-high status in hepato-biliary-pancreatic malignancies in clinical practice and the clinical characteristics of and therapeutic results of pembrolizumab on patients with MSI-high cancers.

Methods

The subjects were 283 patients who had undergone MSI tests for unresectable, metastatic hepato-biliary-pancreatic malignancies at seven hospitals. The tests were polymerase chain reaction fragment analyses using the microsatellite markers consisting of BAT25, BAT26, NR21, NR24, and MONO27. Formalin-fixed, paraffin-embedded blocks, prepared according to the guidelines of the Japan Society of Pathology were used within 4 years after sampling. There were 13 patients with cancers high in MSI, including eight patients receiving pembrolizumab treatment. The clinical characteristics of these patients and therapeutic outcomes of their pembrolizumab treatment were investigated.

Results

MSI-high was detected in 13 (4.6%) of the 283 patients with hepato-biliary-pancreatic malignancies. None of these 13 patients had been diagnosed with Lynch syndrome. Of the Eight patients receiving pembrolizumab, a complete response was observed in three patients, a partial response in one patient, and stable disease in three patients. The objective response rate was 50% and the disease control rate was 87.5%.

Conclusion

MSI-high was detected in 4.6% of patients with hepato-biliary-pancreatic malignancies. There was a 50% objective response rate to pembrolizumab treatment for MSI-high cancers. The evaluation of MSI status by the current method using appropriately prepared tissue samples was to be a reliable and accurate approach to both the determination of MSI status and estimation of the effectiveness of pembrolizumab.
Literature
1.
Viale G, Trapani D, Curigliano G (2017) Mismatch repair deficiency as a predictive biomarker for immunotherapy efficacy. BioMed Res Int 2017:4719194CrossRef
2.
Duffy MJ, Crown J (2019) Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients. Clin Chem 65:1228–1238CrossRef
3.
Rizzo A, Ricci AD, Brandi G (2021) PD-1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer. Cancers 13:558CrossRef
4.
Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520CrossRef
5.
Le DT, Durham JN, Smith KN et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357:409–413CrossRef
6.
Dudley JC, Lin MT, Le DT et al (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22:813–820CrossRef
7.
Hause RJ, Pritchard CC, Shendure J et al (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22:1342–1350CrossRef
8.
Latham A, Srinivasan P, Kemel Y et al (2019) Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol 37:286–295CrossRef
9.
Trabucco SE, Gowen K, Maund SL et al (2019) A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn 21:1053–1066CrossRef
10.
Fujimoto A, Fujita M, Hasegawa T et al (2020) Comprehensive analysis of indels in whole-genome microsatellite regions and microsatellite instability across 21 cancer types. Genome Res 30:315–333CrossRef
11.
Akagi K, Oki E, Taniguchi H et al (2021) Real-world data on microsatellite instability status in various unresectable or metastatic solid tumors. Cancer Sci 112:1105–1113CrossRef
12.
Rashid A, Ueki T, Gao YT et al (2002) K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res 8:3156–3163PubMed
13.
Weinberg BA, Xiu J, Lindberg MR et al (2019) Molecular profiling of biliary cancers reveals distinct molecular alternations and potential therapeutic targets. J Gastrointest Oncol 10:652–662CrossRef
14.
Winkelmann R, Schneider M, Hartmann S et al (2018) Microsatellite instability occurs rarely in patients with cholangiocarcinoma: a retrospective study from a German tertiary care hospital. Int J Mol Sci 19:1421CrossRef
15.
Goeppert B, Roessler S, Renner M et al (2019) Low frequency of mismatch repair deficiency in gallbladder cancer. Diagn Pathol 14:36CrossRef
16.
Kai Y, Ikezawa K, Takada R et al (2021) Success rate of microsatellite instability examination and complete response with pembrolizumab in biliary tract cancer. JGH Open 5:712–716CrossRef
17.
Ando Y, Kumamoto K, Matsukawa H et al (2022) Low prevalence of biliary tract cancer with defective mismatch repair genes in a Japanese hospital-based population. Oncol Lett 23:4CrossRef
18.
Singhi AD, George B, Greenbowe JR et al (2019) Real-time targeted genome profile analysis of pancreatic ductal adenocarcinoma identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology 156:2242-2253.e4CrossRef
19.
Ahmad-Nielsen SA, Bruun Nielsen MFB, Mortensen MB et al (2020) Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma. Pathol Res Pract 216:152985CrossRef
20.
Takano S, Fukasawa M, Shindo H et al (2022) Next-generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer. Cancer Sci 113:1069–1077CrossRef
21.
Kawaoka T, Ando Y, Yamauchi M et al (2020) Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. Hepatol Res 50:885–888CrossRef
22.
Mamdouh S, Aboushousha T, Abdelraouf A et al (2021) Molecular noninvasive diagnosis of hepatocellular carcinoma using microsatellite instability. Asian Pac J Cancer Prev 22:3337–3346CrossRef
23.
Bando H, Okamoto W, Fukui T et al (2018) Utility of the quasi-monomorphic variation range in unresectable metastatic colorectal cancer patients. Cancer Sci 109:3411–3415CrossRef
24.
Piha-Paul SA, Oh DY, Ueno M et al (2020) Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer 147:2190–2198CrossRef
25.
Naito Y, Aburatani H, Amano T et al (2021) Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol 26:233–283CrossRef
26.
Vasen HF, Watson P, Mecklin JP et al (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456CrossRef
27.
Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247CrossRef
28.
29.
Ott PA, Bang YJ, Piha-Paul SA et al (2019) T-cell-inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J Clin Oncol 37:318–327CrossRef
30.
Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10CrossRef
31.
Ueno M, Ikeda M, Morizane C et al (2019) Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomized, multicentre, open-label, phase 1 study. Lancet Gastroenterol Hepatol 4:611–621CrossRef
32.
Kim RD, Chung V, Alese OB et al (2020) A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol 6:888–894CrossRef
Metadata
Title
Microsatellite instability in patients with hepato-biliary-pancreatic malignancies in clinical practice (KHBO 1903)
Authors
Shoji Kubo
Hiroaki Nagano
Masanori Tsujie
Satoru Seo
Kunihito Gotoh
Hiroshi Wada
Shinsuke Nakashima
Tatsuya Ioka
Publication date
19-06-2022
Publisher
Springer Nature Singapore
Published in
International Journal of Clinical Oncology / Issue 8/2022
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-022-02187-9

Other articles of this Issue 8/2022

International Journal of Clinical Oncology 8/2022 Go to the issue

Original Article

Is the ISGPS definition of pancreatic fistula applicable after gastrectomy?

Original Article

Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study)

Original Article

Altered mucosal immunity in HIV-positive colon adenoma: decreased CD4+ T cell infiltration is correlated with nadir but not current CD4+ T cell blood counts

Original Article

Germline sequencing for presumed germline pathogenic variants via tumor-only comprehensive genomic profiling

Original Article

A comparative examination of colorectal cancer burden in European Union, 1990–2019: Estimates from Global Burden of Disease 2019 Study

Original Article

Prevalence and management of methotrexate-induced neurotoxicity in pediatric patients with osteosarcoma: a single-center experience
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits